Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
Dr. McMahon will provide a corporate overview, including a discussion ofthe clinical development program for picoplatin, the Company's lead productcandidate.
A live audio webcast of the presentation will be available for 10 businessdays on the "Events" page of the "News & Events" section of the Company'swebsite at http://www.poniard.com.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc., is a biopharmaceutical company focused onthe development and commercialization of innovative oncology products toimpact the lives of people with cancer. Picoplatin, the Company's leadplatform product candidate, is a new generation platinum chemotherapy. Todate, clinical studies suggest that picoplatin has an improved safety profilerelative to existing platinum-based cancer therapies. Picoplatin is designedto overcome platinum resistance associated with chemotherapy in solid tumors,and is being studied in multiple cancer indications, combinations andformulations. Clinical trials of intravenous picoplatin include a Phase 3trial in small cell lung cancer and Phase 2 trials in metastatic colorectaland castration resistant prostate cancers (also known as hormone refractoryprostate cancer), as well as a clinical trial of oral picoplatin in solidtumors. For additional information please visit http://www.poniard.com.
(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of PoniardPharmaceuticals, Inc.
SOURCE Poniard Pharmaceuticals, Inc.
You May Also Like